万维提示：
1、投稿方式：在线投稿。
2、官网网址：
https://journals.lww.com/co-clinicalnutrition/Pages/default.aspx
3、投稿网址：http://www.editorialmanager.com/cocn/mainpage.html
4、官网邮箱：Sarah.Booth@wolterskluwer.com（总编辑）
5、期刊刊期：双月刊，逢单月出版。
2021年4月30星期五
投稿须知
【官网信息】
Current Opinion in Clinical Nutrition and Metabolic Care
Online Submission and Review System
Author Guidelines
Current Opinion publishes commissioned articles only. Commissioned articles are subject to peer-review. We are unable to consider unsolicited manuscripts for publication.
Please ensure that you follow these guidelines when submitting your manuscript. Manuscripts must be formatted in accordance with these guidelines before they can be accepted for publication.
Aims of the Journal
The Current Opinion journals were developed out of the recognition that specialists have increasing difficulty in keeping up to date with the expanding volume of information published in their subject. We aim to help the reader by providing in a systematic manner:
The views of experts on current advances in the field, in a clear and readable format.
Selections, annotated by experts, of the most interesting papers from the great wealth of original publications.
Authors write short articles in which they present developments in their topic, emphasising the aspects that, in their opinion are the most important. In addition, they provide short annotations to the papers published in their topic during the period reviewed (during the past 12-18 months). This selected bibliography is printed at the end of each review. Papers chosen by a reviewer as being ‘of special interest’ or ‘of outstanding interest’ are clearly identified.
Selection of articles for review
You should aim to review recent articles published in your subject, with particular emphasis on those articles published during the review period (during the past 12-18 months). Older articles MUST be avoided. An exception can be made for one or two classical articles to be cited in the introduction where an outstanding contribution to the field has been made.
Articles containing too many older references will be sent back to you for revision before the paper is sent for editorial review. If there is little recent literature on your given topic then your review should be short to reflect this.
The review should highlight and discuss all interesting developments in your subject, as reflected in the recent literature. In addition to describing recent trends, you are encouraged to give your own opinions of the topics discussed. However, be particularly careful of expressing conclusions in a way that might be construed as biased against a particular researcher, product or manufacturer.
Manuscript format and structure
The review should be double-spaced and approximately 2500 words in length (excluding abstract and references). Reviews less than 2500 words are acceptable when there is not a lot of recent literature on your given topic.
The review must contain the following:
* The lines must be numbered starting with the title page
Title page: stating the title, authors and their affiliations, and full contact details for the corresponding author (including phone number and email address). Current Opinion papers should have a maximum of 3 authors.
Structured Abstract: This should be no longer than 200 words and should not contain any references. The abstract should be structured into the following subheadings:
Purpose of review: describe why this review is timely and relevant.
Recent findings: describe the main themes in the literature covered by the article.
Summary: describe the implications of the findings for clinical practice or research.
Keywords: 3-5 keywords relevant to the paper should be listed.
Introduction: a paragraph outlining the scope of the review and mentioning a maximum of one or two earlier works which will place the review in context. However it is better to cite a recent general review article which cites the pioneering work.
Text of review: include headings and titled paragraphs to subdivide the text. Ensure that at least one sentence divides each heading – double headings are not allowed.
Conclusion: a short paragraph drawing together the implications of the review topic and, if appropriate, giving suggestions for future research. General sentences such as "future research is required" must be avoided.
Key points: 3 to 5 key bullet points which summarise your article should be included after the main body of text. The aim of these is to encourage citations to your article based on the stated key points. Please ensure each key point is no longer than one sentence.
Acknowledgements, Financial Support and Sponsorship, and Conflicts of Interest: Acknowledgements, Financial Support and Sponsorship, and Conflicts of Interest statements should list all possible conflicts of interest in the manuscript, including financial, consultant, institutional and other relationships that might lead to bias or a conflict of interest. This section should contain distinct statements in separate paragraphs:
1. Acknowledgements. Made only to those who have made a substantial contribution to the article. If there was no assistance state: none.
Example: We would like to thank Dr John A. Smith for his assistance with the study.
2. Financial support and sponsorship. You must make reference to all relevant sources of funding concerning this article and include grants and support which are not exclusive to the Current Opinion article. If there were no sources of funding please state: none.
Example: This work was supported by the Department of Anaesthesiology, London Hospital, London, UK.
3. Conflicts of interest. You must make reference to all relevant conflicts of interest concerning this article. If there are no conflicts of interest please state: none.
Example: A has received honoraria from Company Z. B is currently receiving a grant (#12345) from Organisation Y, and C is on the speaker's bureau for Organisation X. For the remaining authors none were declared.
References: References should be in numerical sequence (Vancouver style) and should include the first three authors or all authors if there are four or fewer. References from within the review period (the past 12-18 months) should be annotated and bulleted as detailed below. (See References: further information section at the end of this document).
References cited in figures or tables must be numbered in numerical order in accordance with the position of the figure or table citation in the article. For example, if your figure/table cites two references and the first time you refer to your figure/table is after you cite reference 15, then the two references in your figure/table should be numbered 16 and 17. The next reference you cite following the figure citation should be reference 18. In the text, this example would be referenced as follows: Dulce locum sepre [15] amrus a sentis (Table 1). Dondus rensil anpris sando [18].
Bullets and annotations: The important references from the review period must have one or two bullets and an annotation explaining why they are of interest. These are a key feature of Current Opinion journals. Any annotations on references from outside of the review period will be removed.
Bulleted references must
Have been published during the period reviewed by the issue (during the past 12-18 months).
Have one bullet (*) for special interest and two bullets (**) for outstanding interest.
Be annotated with a brief description of the paper's importance.
When referencing and annotating your own work from previously published material you are limited to one bullet point.
Examples of bulleted and annotated references are shown below. * Seror R, Sordet C, Guillevin L, et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjo¨ gren's syndrome. Ann Rheum Dis 2015; 66:351-357.
This is the first clinical trial to demonstrate the efficacy of B-cell depletion in SjS. This article highlights the importance of B cells in the pathogenesis of SjS.
** Lavie F, Miceli-Richard C, Ittah M, et al. Increase of B-cell activating factor of the TNF family (BAFF) after rituximab: insights into a new regulating system of BAFF production. Ann Rheum Dis 2015; 66:700–703.
This study describes the elevation in BAFF levels that occurs in serum of patients who have been treated with B-cell depleting agents. This observation may have important consequences, following treatment, in promoting the corruption of B-cell tolerance and leading to disease relapse.
Figures and Tables: must be cited in the article. Figure titles and figure legends must be provided for all figures and should be included in the main body of the text following the references. Please use either Arial or Helvetica font size 7 for any text or labels within figures.
All illustrations should be labelled as figures, and should be cited in the article in numerical order. Figures should have a title and a legend describing the figure in full. All abbreviations used in figures and not in the main text should be defined at the end of the figure legend.
Tables should be used to tabulate data discussed in further detail in the review. Tables must be cited in the main text of the article and have an appropriate title.
Colour figures: There is a $1000 charge to authors if figures are to be produced in colour. There is no charge for figures to be produced in black and white. If you are submitting colour figures, please indicate if you are willing to cover this cost.
Figures and Tables must be:
Original whenever possible
Clearly marked as "original" or "previously published" upon submission
Accompanied by full source details when not original. When reusing previously published figures please ensure they are the same as the original and not adapted.
Figures and tables should not be embedded within the text but should be submitted as separate files.
Figures should be in JPEG, TIFF, EPS, PPT or WORD formats and should have a resolution of at least 300 dpi to be suitable for printing. Please see Creating Digital Artwork (PDF) for the full digital artwork requirements.
When reusing previously published figures please ensure they are the same as the original and not adapted. Please obtain the artwork and provide full source details. We will seek the Publisher's permission to reproduce such figures.
Exceptions: We are happy to seek publisher’s permission for all figures except those previously published in the Journal of the American Medical Association (JAMA) or the American Association for Cancer Research Journal (AACR). These publishers charge a significant fee to reproduce their figures. If you wish to use a figure from their publications you should apply for permission yourself and send confirmation to the editorial office.
Abbreviations should be used sparsely and should be defined on their first appearance. Any abbreviations that are not accepted by international bodies should be avoided.
Manufactured products, equipment and drugs: give the manufacturer, town (state) and country in brackets.
Quotations: the source should be referenced, and the page number given in brackets in the text.
Supplementary material
We have the facility to include additional or supplementary information (e.g. tables/figures/videos/audio) with articles. This supplementary material will be published online only and will not appear in the print issue. For more details, click here or contact the Editorial Coordinator.
Submitting your paper
Manuscripts should be submitted via the online submission site, Editorial Manager. Your username and password will have been sent to you by email.
Click ‘login’ and then enter your username and password and click ‘author login’.
Please click ‘update my information’ from the black menu bar at the top of the screen and ensure that we have your correct address and telephone number on record.
Click on ‘my accepted invitations’ to begin the submission process, and follow the steps onscreen.
Figures and tables should be submitted as separate files. The manuscript file should include the text, references, structured abstract, keywords, figure legends and author address.
We cannot publish your paper without all authors completing the disclosure and copyright information online. This is part of the submission process.
Redundant or duplicate publication
We ask you to confirm that your paper has not been published in its current form or a substantially similar form (in print or electronically, including on a web site), that it has not been accepted for publication elsewhere, and that it is not under consideration by another publication. The ICMJE has provided details of what is and what is not duplicate or redundant publication. If you are in doubt, we ask you to contact the Editorial Office with details of the relevant previously published work or work under consideration by other journals. We will respond with advice on how to proceed.
Copyright Transfer Agreement
Each author must complete the journal's copyright transfer agreement online. All authors must be listed on submission. Automatic emails will then be sent out detailing how to complete the online Copyright Transfer Agreement..
Open access
LWW's hybrid open access option is offered to authors whose articles have been accepted for publication. With this choice, articles are made freely available online immediately upon publication. Authors may take advantage of the open access option at the point of acceptance to ensure that this choice has no influence on the peer review and acceptance process. These articles are subject to the journal's standard peer-review process and will be accepted or rejected based on their own merit.
Authors of accepted peer-reviewed articles have the choice to pay a fee to allow perpetual unrestricted online access to their published article to readers globally, immediately upon publication. The article processing charge (APC) is charged on acceptance of the article and should be paid within 30 days by the author, funding agency or institution. Payment must be received in full for the article to be published open access. For pricing, please visit our Wolters Kluwer Open Health Journals page.
Authors retain copyright
Authors retain their copyright for all articles they opt to publish open access. Authors grant LWW a license to publish the article and identify itself as the original publisher.
Creative Commons license
Articles opting for open access will be freely available to read, download and share from the time of publication. Articles are published under the terms of the Creative Commons License Attribution-NonCommerical No Derivative 3.0 which allows readers to disseminate and reuse the article, as well as share and reuse of the scientific material. It does not permit commercial exploitation or the creation of derivative works without specific permission. To view a copy of this license visit: http://creativecommons.org/licenses/by-nc-nd/3.0.
Compliance with NIH, RCUK, Wellcome Trust and other research funding agency accessibility requirements
A number of research funding agencies now require or request authors to submit the post-print (the article after peer review and acceptance but not the final published article) to a repository that is accessible online by all without charge. As a service to our authors, LWW identifies to the National Library of Medicine (NLM) articles that require deposit and transmits the post-print of an article based on research funded in whole or in part by the National Institutes of Health, Howard Hughes Medical Institute, or other funding agencies to PubMed Central. The revised Copyright Transfer Agreement provides the mechanism. LWW ensures that authors can fully comply with the public access requirements of major funding bodies worldwide. Additionally, all authors who choose the open access option will have their final published article deposited into PubMed Central.
RCUK and Wellcome funded authors can choose to publish their paper as open access with the payment of an article process charge (gold route), or opt for their accepted manuscript to be deposited (green route) into PMC with an embargo.
With both the gold and green open access options, the author will continue to complete the Copyright Transfer Agreement online as it provides the mechanism for LWW to ensure that the author is fully compliant with the requirements. After completing the CTA, the author will then sign a License to Publish where they will then own the copyright. Those authors who wish to publish their article via the gold route will be able to publish under the terms of the Attribution 3.0 (CCBY) License. To view of a copy of this license visit: http://creativecommons.org/licenses/by/2.0/. Those authors who wish to publish their article via the green route will be able to publish under the rights of the Attribution Non-commercial 3.0 (CCBY NC) license (http://creativecommons.org/licenses/by-nc/2.0/).
It is the responsibility of the author to inform the Editorial Office and/or LWW that they have RCUK funding. LWW will not be held responsible for retroactive deposits to PMC if the author has not completed the proper forms.
FAQ for open access
http://links.lww.com/LWW-ES/A48
Compliance with NIH and Other Research Funding Agency Accessibility Requirements
A number of research funding agencies now require or request authors to submit the post-print (the article after peer review and acceptance but not the final published article) to a repository that is accessible online by all without charge. As a service to our authors, LWW will identify to the National Library of Medicine (NLM) articles that require deposit and will transmit the post-print of an article based on research funded in whole or in part by the National Institutes of Health, Wellcome Trust, Howard Hughes Medical Institute, or other funding agencies to PubMed Central. The copyright transfer agreement provides the mechanism.
References: further information
Articles (published or in press) should be included in the reference list at the end of the review. They should be numbered consecutively in the order in which they are cited in the text (Vancouver style). Abstracts should also be entered in the reference list with full publication details of the source. Every study mentioned in the text must be accompanied by a relevant reference.
Unpublished data, submitted manuscripts and personal communications must be referenced in the text as follows:
Personal communication: (Churchill SW, personal communication).
Submitted paper: (Bell S, Gordon S, unpublished data).
You are responsible for the accuracy of references and for obtaining permission to use personal communications.
Reference format
In the text, reference citations should be typed inside square brackets, e.g.[1]. Asterisks should be used to indicate bulleted references, e.g. [1,2,3*,4**]. In the reference list, bulleted references should include the asterisk to the left of the number, with the annotation beneath the reference details (see below).
Please list the first three authors for each reference and then et al, unless there are four authors or fewer, in which case all authors should be listed. Provide full reference details (author(s), title, journal, year, volume, pages). Capitalise the first letter and all initials of authors’ names, the first letter of the title of the paper, and any proper nouns in the title. Journal names should be abbreviated as in the Index Medicus. If you are not familiar with the appropriate abbreviation, the journal name should be given in full.
References should be structured as follows:
Journal:
* Author A, Author B, Author C. Title of the paper. Journal Abbreviation 2015; 4:25—27.
With annotation describing importance of reference, if bulleted
Book:
* Author A, Author B, Author C. Title of the book section. In: Book name. Edition number. Edited by Editor A, Editor B, Editor C (editors). Location of Publisher: Publisher; 2015. pp. 25—27.
With annotation describing the importance of the reference, if bulleted.
Annotations should highlight the importance of papers published during the review period. Annotations should not summarise the content of a paper. 75–80% of papers published during the period of review should be given one bullet and have a short (one or two line) annotation describing the paper’s interest to the reader. Papers that are of outstanding interest and are essential reading should be given two bullets and a more comprehensive annotation.
At least 80% of the references in a review must be from the review period (published in the past year to 18 months) with the exception of one or two references which should be less than three years old. Most of these references should have one or two bullets and annotations.
Any annotations on references from outside of the review period will be removed unless a justification is submitted to the journal office.
Please do not hesitate to contact the Editorial Office if you have any questions. You can click the ‘contact us’ button at the top of the screen to email us directly.
Please refer to the Submission Checklist before uploading your paper. An example manuscript is also available from the journal website.
When your paper has been reviewed by the editors, please make changes according to the following format:
* The lines should be numbered
*Please submit a tracked version of the paper so that the editors can find your changes
*Please provide a point-by-point answer to the comments
